Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.54 |
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.50 |
| ▸ | FNTA | P49354 | 3/20 | 0.48 |
| ▸ | FNTB | P49356 | 3/20 | 0.48 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 4/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29585814 | 0.97 | MME (0.52) | MMENOD1FNTAFNTBPGGT1B | |
| SCHEMBL30811192 | 0.90 | FOLH1 (0.49) | MMENOD1FNTAFNTBPGGT1B | |
| SCHEMBL29454516 | 0.90 | MME (0.46) | MMENOD1FNTAFNTBPGGT1B | |
| SCHEMBL30811169 | 0.89 | NOD1 (0.47) | MMENOD1FNTAFNTBPGGT1B | |
| SCHEMBL29376792 | 0.88 | DPP7 (0.58) | NOD1DPP4DPP9DPP7DPP8 | |
| SCHEMBL2850058 | 0.88 | DPP7 (0.58) | NOD1DPP4DPP9DPP7DPP8 | |
| SCHEMBL29399358 | 0.87 | DPP7 (0.54) | MMENOD1DPP4DPP9DPP7 | |
| SCHEMBL29692729 | 0.87 | DPP7 (0.59) | MMENOD1DPP4DPP9DPP7 | |
| SCHEMBL9052383 | 0.86 | DPP7 (0.53) | MMENOD1DPP4DPP9DPP7 | |
| SCHEMBL29743020 | 0.85 | CPB2 (0.49) | NOD1FNTAFNTBPGGT1BACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
| US-12023378-B2 | Covalently linked antigen-antibody conjugates | HOFFMANN-LA ROCHE INC. (US) | 2024-07-02 | — | — | US | disclosed |
| CN-113087789-B | Filamentous phage pVIII protein monoclonal antibody and application thereof | 中国农业大学 | 2022-09-23 | — | — | CN | disclosed |
| US-11273223-B2 | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles | HOFFMANN-LA ROCHE INC. (US) | 2022-03-15 | — | — | US | disclosed |
| EP-3960768-A1 | BISPECIFIC ANTI-HAPTEN/ANTI-BLOOD BRAIN BARRIER RECEPTOR ANTIBODIES, COMPLEXES THEREOF AND THEIR USE AS BLOOD BRAIN BARRIER SHUTTLES | F. Hoffmann-La Roche AG (CH) | 2022-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | MME 130/4885NOD1 1477/4885FNTA 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.